Breaking News Instant updates and real-time market news.

MRK

Merck

$80.25

1.03 (1.30%)

, AZN

AstraZeneca

$37.92

0.54 (1.44%)

16:20
06/03/19
06/03
16:20
06/03/19
16:20

Merck's Lynparza study demonstrated 72% ORR in Phase 3 Solo3 trial

AstraZeneca (AZN) and Merck (MRK) presented full results from the Phase 3 SOLO3 trial which evaluated LYNPARZA, compared to chemotherapy, for the treatment of platinum-sensitive relapsed patients with germline BRCA1/2-mutated advanced ovarian cancer, who have received two more prior lines of chemotherapy. The results were presented at the 55th ASCO in Chicago. The results from the trial showed a "statistically-significant and clinically-meaningful improvement in objective response rate, or ORR, in the LYNPARZA arm compared to the chemotherapy arm, with ORR of 72.2% for LYNPARZA vs 51.4% for chemotherapy. The key secondary endpoint of progression-free survival was also significantly increased in the LYNPARZA arm at 13.4 months compared to the chemotherapy arm of 9.2 months. The safety and tolerability profile of LYNPARZA in SOLO3 was consistent with previous trials.

MRK

Merck

$80.25

1.03 (1.30%)

AZN

AstraZeneca

$37.92

0.54 (1.44%)

  • 03

    Jun

  • 03

    Jun

  • 06

    Jun

  • 17

    Jun

  • 20

    Jun

  • 20

    Jun

  • 20

    Jun

  • 16

    Jul

  • 30

    Jul

  • 06

    Aug

  • 20

    Sep

MRK Merck
$80.25

1.03 (1.30%)

05/21/19
MSCO
05/21/19
NO CHANGE
Target $84
MSCO
Overweight
Morgan Stanley not lowering Keytruda projections despite Merck disappointment
After Merck announced that Keytruda monotherapy failed to beat chemotherapy in a Phase 3 triple negative breast cancer, or TNBC, trial, Morgan Stanley analyst David Risinger said he is not r lowering his Keytruda projections as he is hopeful that the drug can succeed in KN-355, another TNBC trial, later this year. In that trial, a combination of Keytruda plus chemo will be investigated in first-line TNBC, noted Risinger, who has an Overweight rating and $84 price target on Merck shares.
05/22/19
GUGG
05/22/19
NO CHANGE
GUGG
Buy
Guggenheim says Peloton Therapeutics a good strategic fit for Merck
Guggenheim analyst Seamus Fernandez said he thinks Peloton Therapeutics is a good strategic fit for Merck citing the "rational targeting" of a resistance mechanism to VEGF-TKIs commonly used in the treatment of Renal Cell Carcinoma, or RCC. Fernandez, who sees the transaction being minimally dilutive and having no impact on 2019 adjusted EPS guidance, keeps a Buy rating on Merck shares.
05/28/19
GSCO
05/28/19
INITIATION
Target $85
GSCO
Neutral
Merck initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst Terence Flynn started Merck with a Neutral rating and $85 price target. The analyst projects the company's earnings and revenue growth through 2022 will be in-line with consensus. As such, he views the stock as fairly valued.
05/30/19
GUGG
05/30/19
NO CHANGE
GUGG
Buy
Array BioPharma could be seen as target after 'de-risking' data, says Guggenheim
Guggenheim analyst Michael Schmidt said Array Biopharma (ARRY) may be perceived by investors as a theoretical acquisition target following the disclosure of Phase 3 interim results of Braftovi/Mektovi in BRAF+ colorectal cancer, which he views as positive and a "de-risking event." 67% of announced acquisitions in oncology with a comparable market cap to Array had what he would consider major pipeline de-risking events in the 6 months prior to their deal announcements, Schmidt tells investors. Merck (MRK) and Pfizer (PFE) "seem to have most bandwidth for a deal," said Schmidt, who added that those two along with Bristol-Myers (BMY), AstraZeneca (AZN) and Roche (RHHBY) scored highest as possible large cap theoretical acquirers of Array in his analysis. Schmidt raised his price target on Array Biopharma shares to $38 from $37, though his analysis suggests a potential $40-$50 acquisition price if the company were to be bought.
AZN AstraZeneca
$37.92

0.54 (1.44%)

05/29/19
HCWC
05/29/19
NO CHANGE
HCWC
Buy
AstraZeneca decision does not impact MEDI0457, says H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju says AstraZeneca's (AZN) decision to discontinue activities related to two new DNA-based cancer vaccine candidates from Inovio (INO) does not affect MEDI0457. AstraZeneca continues to pursue the development of MEDI0457, which is being evaluated in combination with durvalumab in multiple Phase 2 studies in HPV-related cancers, Selvaraju tells investors in a research note. Inovio is eligible to receive up to $700M potential milestone payments, including $250M related to MEDI0457, says the analyst. He reiterates a Buy rating on Inovio with a $13 price target.
05/29/19
CANT
05/29/19
NO CHANGE
Target $12
CANT
Overweight
Inovio milestones from Astra still worth up to $250M, says Cantor Fitzgerald
Inovio (INO) announced that it received notification from MedImmune, a subsidiary of AstraZeneca (AZN), that it plans to discontinue research collaboration programs except for the MEDI0457/ durvalumab combo studies that are in multiple Phase 2 trials in patients with HPV associated cancers, Cantor Fitzgerald analyst Charles Duncan tells investors in a research note. Despite "strained optics," the collaboration change makes sense, says the analyst. He estimates Inovio's MEDI0457 milestones are worth up to $250M and keeps an Overweight rating on the shares with a $12 price target.
05/30/19
SBSH
05/30/19
NO CHANGE
Target $7
SBSH
Buy
Inovio risk/reward attractive into data readouts, says Citi
Citi analyst Joel Beatty lowered his price target for Inovio Pharmaceuticals (INO) to $7 from $10 after AstraZeneca (AZN) decided to discontinue activities with respect to its rights to co-develop up to two new DNA-based cancer vaccine product candidates. The analyst, however, says this is a good time to buy shares of Inovio. The company has three phase 1/2 immuno-oncology combo trials expected to readout in the second half of 2019, and the stock's risk/reward is attractive into the news, Beatty tells investors in a research note.

TODAY'S FREE FLY STORIES

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
10/22/19
10/22
15:16
10/22/19
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$338.80

7.68 (2.32%)

15:15
10/22/19
10/22
15:15
10/22/19
15:15
Hot Stocks
Breaking Hot Stocks news story on Boeing »

Boeing confirms Deal to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

BA

Boeing

$339.26

8.14 (2.46%)

15:10
10/22/19
10/22
15:10
10/22/19
15:10
Periodicals
Boeing commercial airline executive leaving company, NY Times says »

Kevin McAllister, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

BA

Boeing

$338.69

7.57 (2.29%)

15:07
10/22/19
10/22
15:07
10/22/19
15:07
Periodicals
Breaking Periodicals news story on Boeing »

Boeing head of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

CMG

Chipotle

$824.48

-27.4 (-3.22%)

15:04
10/22/19
10/22
15:04
10/22/19
15:04
Options
Chipotle options imply 10.7% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 12

    Nov

HOG

Harley-Davidson

$40.65

3.515 (9.47%)

15:02
10/22/19
10/22
15:02
10/22/19
15:02
Recommendations
Harley-Davidson analyst commentary  »

Harley-Davidson estimates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

TTD

Trade Desk

$189.94

-10.99 (-5.47%)

, ROKU

Roku

$127.31

-5.63 (-4.24%)

15:02
10/22/19
10/22
15:02
10/22/19
15:02
Recommendations
Trade Desk, Roku analyst commentary  »

SunTrust reiterates a Buy…

TTD

Trade Desk

$189.94

-10.99 (-5.47%)

ROKU

Roku

$127.31

-5.63 (-4.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

  • 07

    Nov

  • 19

    Nov

  • 21

    Nov

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$300.08

0.03 (0.01%)

14:58
10/22/19
10/22
14:58
10/22/19
14:58
General news
U.K. government not ruling out seeking short Brexit delay, Bloomberg says »

Bloomberg cites comments…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$300.08

0.03 (0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNAP

Snap

$14.04

-0.54 (-3.70%)

, FB

Facebook

$183.72

-6.1 (-3.21%)

14:57
10/22/19
10/22
14:57
10/22/19
14:57
On The Fly
Fly Intel: What to watch in Snap earnings report »

Snap Inc. (SNAP) is…

SNAP

Snap

$14.04

-0.54 (-3.70%)

FB

Facebook

$183.72

-6.1 (-3.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 27

    Oct

  • 30

    Oct

  • 21

    Nov

SERV

ServiceMaster

$45.81

-10.26 (-18.30%)

14:54
10/22/19
10/22
14:54
10/22/19
14:54
Recommendations
ServiceMaster analyst commentary  »

ServiceMaster weakness an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

  • 12

    Nov

  • 13

    Nov

  • 14

    Nov

  • 15

    Nov

  • 19

    Nov

WFC

Wells Fargo

$50.82

0.37 (0.73%)

14:54
10/22/19
10/22
14:54
10/22/19
14:54
Downgrade
Wells Fargo rating change  »

Wells Fargo downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 29

    Oct

  • 12

    Nov

  • 14

    Jan

SNAP

Snap

$14.08

-0.5 (-3.43%)

14:49
10/22/19
10/22
14:49
10/22/19
14:49
Options
Snap Inc. options imply 26.3% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 21

    Nov

GILD

Gilead

$66.32

1.11 (1.70%)

14:45
10/22/19
10/22
14:45
10/22/19
14:45
Options
Gilead call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 06

    Nov

  • 07

    Dec

SPY

SPDR S&P 500 ETF Trust

$300.58

0.53 (0.18%)

, SPX

S&P 500

$0.00

(0.00%)

14:41
10/22/19
10/22
14:41
10/22/19
14:41
General news
U.K. Parliament rejects timetable bill for exit from EU »

U.K. lawmakers rejected a…

SPY

SPDR S&P 500 ETF Trust

$300.58

0.53 (0.18%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$340.23

9.11 (2.75%)

14:34
10/22/19
10/22
14:34
10/22/19
14:34
On The Fly
Fly Intel: What to watch in Boeing's earnings report »

Boeing (BA) is scheduled…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

FB

Facebook

$183.45

-6.37 (-3.36%)

, GOOG

Alphabet

$1,246.51

0.28 (0.02%)

14:25
10/22/19
10/22
14:25
10/22/19
14:25
Periodicals
U.S antitrust chief says breakup of 'Big Tech' is 'on the table,' WSJ reports »

Makan Delrahim, the U.S.…

FB

Facebook

$183.45

-6.37 (-3.36%)

GOOG

Alphabet

$1,246.51

0.28 (0.02%)

AMZN

Amazon.com

$1,769.36

-15.37 (-0.86%)

AAPL

Apple

$242.10

1.61 (0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

  • 24

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 21

    Nov

GME

GameStop

$6.30

0.37 (6.24%)

14:25
10/22/19
10/22
14:25
10/22/19
14:25
Options
GameStop call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

SPY

SPDR S&P 500 ETF Trust

$300.50

0.45 (0.15%)

, SPX

S&P 500

$0.00

(0.00%)

14:17
10/22/19
10/22
14:17
10/22/19
14:17
General news
Brexit withdrawal agreement bill passes by 329-299 vote, Bloomberg reports »

The U.K. Parliament is…

SPY

SPDR S&P 500 ETF Trust

$300.50

0.45 (0.15%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
10/22/19
10/22
14:17
10/22/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
10/22/19
10/22
14:16
10/22/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:10
10/22/19
10/22
14:10
10/22/19
14:10
Conference/Events
Senate Commerce, Science & Transportation Committee to hold a hearing »

The Subcommittee on…

UTX

United Technologies

$141.32

3.08 (2.23%)

, BA

Boeing

$339.38

8.26 (2.49%)

14:09
10/22/19
10/22
14:09
10/22/19
14:09
Periodicals
United Tech sees no extra cut in Boeing 737 MAX production in 2019, Reuters says »

United Technologies (UTX)…

UTX

United Technologies

$141.32

3.08 (2.23%)

BA

Boeing

$339.38

8.26 (2.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

LLY

Eli Lilly

$109.84

1.9 (1.76%)

14:09
10/22/19
10/22
14:09
10/22/19
14:09
Earnings
Fly Intel: What to watch in Eli Lilly earnings report »

Eli Lilly (LLY) is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 28

    Oct

FCX

Freeport McMoRan

$9.95

0.13 (1.32%)

14:05
10/22/19
10/22
14:05
10/22/19
14:05
Options
Freeport McMoRan call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

WBS

Webster Financial

$44.80

-2.51 (-5.31%)

14:01
10/22/19
10/22
14:01
10/22/19
14:01
Downgrade
Webster Financial rating change  »

Compass Point cuts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 13

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.